Nanjing Well Pharmaceutical Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.039x

Nanjing Well Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Nanjing Well Pharmaceutical Co Ltd (603351) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥69.51 Million ≈ $10.17 Million USD) by net assets (CN¥1.77 Billion ≈ $258.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Nanjing Well Pharmaceutical Co Ltd (2014–2025)

Cash flow conversion efficiency of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. This chart illustrates how Nanjing Well Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Nanjing Well Pharmaceutical Co Ltd share price for real-time trading data and today's change.

Nanjing Well Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained

Nanjing Well Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Nanjing Well Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nanjing Well Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Nanjing Well Pharmaceutical Co Ltd market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
LSI Industries Inc NASDAQ:LYTS	0.101x
China Hi-Tech Group Co Ltd SHG:600730	-0.008x
Chularat Hospital Public Company Limited BK:CHG	0.032x
Canadian Tire Corporation Limited TO:CTC	0.117x
Hainan Haiqi Transportation Group Co Ltd SHG:603069	-0.017x
Delixi Xinjiang Transp Co Ltd SHG:603032	0.024x
Ur Energy Inc NYSE MKT:URG	-0.166x
Ability Opto-Electronics Technology Co Ltd TWO:3362	-0.001x

Annual Cash Flow Conversion Efficiency for Nanjing Well Pharmaceutical Co Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. Review free cash flow generation of Nanjing Well Pharmaceutical Co Ltd to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥1.80 Billion ≈ $263.81 Million	CN¥238.24 Million ≈ $34.86 Million	0.132x	+1.78%
2024-12-31	CN¥1.71 Billion ≈ $249.96 Million	CN¥221.79 Million ≈ $32.46 Million	0.130x	+71.98%
2023-12-31	CN¥1.59 Billion ≈ $233.06 Million	CN¥120.24 Million ≈ $17.60 Million	0.075x	+2.69%
2022-12-31	CN¥1.48 Billion ≈ $216.92 Million	CN¥108.99 Million ≈ $15.95 Million	0.074x	+982.90%
2021-12-31	CN¥1.39 Billion ≈ $202.73 Million	CN¥-11.54 Million ≈ $-1.69 Million	-0.008x	-111.60%
2020-12-31	CN¥1.30 Billion ≈ $190.18 Million	CN¥93.30 Million ≈ $13.65 Million	0.072x	-31.29%
2019-12-31	CN¥1.24 Billion ≈ $181.63 Million	CN¥129.69 Million ≈ $18.98 Million	0.104x	+0.72%
2018-12-31	CN¥614.61 Million ≈ $89.94 Million	CN¥63.76 Million ≈ $9.33 Million	0.104x	-22.45%
2017-12-31	CN¥532.80 Million ≈ $77.96 Million	CN¥71.27 Million ≈ $10.43 Million	0.134x	-53.67%
2016-12-31	CN¥443.99 Million ≈ $64.97 Million	CN¥128.18 Million ≈ $18.76 Million	0.289x	+4.79%
2015-12-31	CN¥294.49 Million ≈ $43.09 Million	CN¥81.14 Million ≈ $11.87 Million	0.276x	-11.25%
2014-12-31	CN¥240.35 Million ≈ $35.17 Million	CN¥74.62 Million ≈ $10.92 Million	0.310x	--

About Nanjing Well Pharmaceutical Co Ltd

SHG:603351 China Drug Manufacturers - Specialty & Generic

Market Cap

$534.72 Million

CN¥3.65 Billion CNY

Market Cap Rank

#11535 Global

#3253 in China

Share Price

CN¥26.98

Change (1 day)

-2.07%

52-Week Range

CN¥22.85 - CN¥30.12

All Time High

CN¥40.56